Analysts Issue Forecasts for GSK's Q1 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK - Free Report) - Equities researchers at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for GSK in a report issued on Wednesday, December 11th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings per share of $1.10 for the quarter, down from their previous forecast of $1.11. The consensus estimate for GSK's current full-year earnings is $4.02 per share. Zacks Research also issued estimates for GSK's Q3 2025 earnings at $1.33 EPS, Q4 2025 earnings at $0.79 EPS, FY2025 earnings at $4.24 EPS and FY2026 earnings at $4.73 EPS.

A number of other research analysts also recently weighed in on the stock. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday. Barclays upgraded GSK to a "hold" rating in a research note on Tuesday, August 27th. Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and reduced their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Finally, Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Stock Performance

GSK traded down $0.23 during midday trading on Friday, hitting $33.94. 1,988,224 shares of the company traded hands, compared to its average volume of 4,152,852. The company's 50-day moving average is $36.28 and its 200 day moving average is $39.36. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $70.34 billion, a PE ratio of 22.19, a price-to-earnings-growth ratio of 1.54 and a beta of 0.64. GSK has a 52 week low of $32.83 and a 52 week high of $45.92.

Institutional Trading of GSK

Several hedge funds have recently bought and sold shares of the stock. Eastern Bank bought a new stake in shares of GSK in the third quarter worth about $26,000. Sunbelt Securities Inc. increased its stake in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Concord Wealth Partners raised its holdings in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock worth $32,000 after acquiring an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of GSK during the 2nd quarter valued at approximately $37,000. Finally, Fortitude Family Office LLC purchased a new position in shares of GSK in the third quarter valued at $42,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

Insider Activity

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company's stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 10.00% of the company's stock.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.63%. The ex-dividend date is Friday, November 15th. This is a positive change from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio is presently 99.35%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.